Isomab Ltd
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
7-day free trial · no credit card
Verified contacts
6
available on Kipplo
LinkedIn employees
12
1 to 10 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 6 verified contacts at Isomab Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
6 contacts with verified email or phone · masked until revealed.
- KM
Kishor Modha
Vice President of Product Development · Sales & Business Development
EmailPhone - SY
Simon Yates
Ip Portfolio Manager · Science
EmailPhone - AP
Amanda Pujolas
Executive Assistant · General Business & Management
EmailPhone
Showing 3 of 6 verified contacts
Top roles at Isomab Ltd
5 distinct titles indexed · top 5 shown.
- 2ip portfolio manager
- 1()
- 1executive assistant
- 1project manager - drug development
- 1vice president of product development
Sign up to unlock all 6 contacts at Isomab Ltd
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 6 verified contacts at Isomab Ltd
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.